Zim Laboratories Limited (ZIMLAB)

Loading page…

Zim Laboratories Limited (ZIMLAB) · mywealthgrid

About

Zim Laboratories manufactures generic pharmaceuticals with a market capitalization of ₹575 Cr. Recent quarters show sharp deterioration: revenue declined 14.4% from ₹108.66 Cr (Dec 2025) to ₹93.05 Cr (Jun 2026), while operating margins collapsed and the company posted losses.

Face value: ₹10

Market cap

₹733 Cr

P/E

198.1×

P/B

2.5×

Dividend yield

ROE

2.1%

ROCE

6.5%

Debt / equity

0.42

OPM

EPS (TTM)

₹0.7

Book value

₹55.4

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Revenue decline of 14.4% in six months (₹108.66 Cr to ₹93.05 Cr); verify whether loss reflects market share erosion, customer concentration risk, or competitive price pressure

Operating margin compression of 9.2 percentage points (11.79% in Dec 2025 to 2.58% in Jun 2026) with recent operating losses (₹–3.88 Cr, Jun 2026) — determine if driven by pricing pressure, input cost inflation, or underutilized capacity

PE of 155.51 is extreme for current earnings; ROE of 2.13% indicates minimal capital returns; stock must achieve substantial earnings recovery to justify valuation

Earnings swung from ₹4.4 Cr profit (Dec 2025) to ₹–3.88 Cr loss (Jun 2026) with minimal institutional participation (FII 0.03%, DII 1.33%), suggesting limited analyst coverage and high forecast uncertainty

Generated analysis · source review pending

Growth drivers

Revenue stabilization: revenue fell 14.4% from ₹108.66 Cr (Dec 2025) to ₹93.05 Cr (Jun 2026); verify if decline is temporary or reflects permanent market share loss

Margin recovery from depressed levels: OPM at 2.58% (Jun 2026) sits 9.2 percentage points below Dec 2025 peak of 11.79%; verify whether compression stems from temporary cost pressures or structural competitive erosion

Verify: new product approvals, government tender wins, or export market participation that could drive volume and offset domestic pricing pressure

Generated analysis · source review pending

2,034 historical price candles were omitted because the exchange source has not been verified.

₹137.0+1.6%1Y

Quick read

rule-based

Pros

No positive flags triggered.

Cons

−Low return on equity of 5% (3-yr avg)
−Profit declined 4.4% a year over the last 5 years
−Modest revenue growth of 4% a year over the last 5 years
−Weak interest coverage of 1.6×
−Expensive at 198.1× trailing earnings
−Promoter holding fell 2.9 pts over the last year

Research score

Structured signal from quality, growth, valuation and momentum.

26/100

Business quality: 20
Growth: 33
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	307	333	399	367	379	374
COGS	159	160	199	171	168	165
Gross profit	149	173	200	196	211	209
	109	132	148	155	167	179
	40	41	52	41	44	30
OPM %	12.9%	12.3%	13.1%	11.3%	11.5%	8%
Depreciation	16	16	17	16	20	20
Interest	11	8	6	7	11	13
	-3	4	6	5	6	11
Profit before tax	10	21	35	24	18	8
Tax	3	6	11	6	6	2
Tax %	28.5%	30.9%	30.9%	27.1%	32.4%	28.9%
	7	15	24	17	12	6
PAT margin %	2.4%	4.4%	6.1%	4.7%	3.2%	1.6%
EPS (₹)	—	—	5	3.5	2.5	1.2
EPS adjusted (₹)	1.5	3	5	3.5	2.5	1.1
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	8	16	16	16	16	49	49	49	54
Reserves	129	135	138	145	159	152	190	204	243
	70	62	77	81	51	60	106	112	123
	92	115	94	83	115	82	102	108	120
Total equity & liabilities	298	328	325	325	342	342	447	472	539
	94	106	116	107	106	109	161	164	162
CWIP	5	8	5	5	5	18	24	44	59
Investments	0	0	0	0	0	0	0	0	0
	199	215	205	214	231	215	262	264	319
Total assets	298	328	325	325	342	342	447	472	539

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	48.4%	51.9%	50.1%	53.3%	55.7%	55.8%
EBITDA margin %	12.9%	12.3%	13.1%	11.3%	11.5%	8%
EBIT margin %	7.8%	7.5%	8.7%	6.9%	6.2%	2.7%
PAT margin %	2.4%	4.4%	6.1%	4.7%	3.2%	1.6%
Working capital
Receivable days	86	98	87	100	103	106
Inventory days	125	171	99	173	188	207
Payable days	149	185	107	133	151	161
NWC days	62	85	79	140	140	152
Leverage
Current ratio	1.35	1.45	1.72	1.43	1.39	1.45
Debt to EBITDA	2.04	1.25	1.15	2.57	2.57	4.1
Debt to equity	0.5	0.29	0.3	0.45	0.44	0.42
Interest coverage	2.4	3.5	7.3	4.4	2.6	1.6
Asset turnover	0.95	0.98	1.17	0.82	0.8	0.69
Return ratios
Return on assets %	2.3%	4.3%	7.2%	3.9%	2.6%	1.1%
Return on capital employed %	14.4%	15.5%	19.2%	11.8%	9.9%	6.5%
Return on equity %	4.6%	8.3%	12.2%	7.2%	4.8%	2%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	33.26%	33.26%	33.26%	33.26%	33.26%	33.26%	33.26%	33.26%	33.26%	33.26%	30.35%	30.36%
	0%	0%	0.01%	0%	0%	0.21%	0.01%	0.03%	0%	0.02%	0%	0.03%
	0%	0%	0%	0.11%	0.1%	0.24%	0.24%	0.24%	0.24%	0.2%	0.07%	1.33%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	66.74%	66.74%	66.73%	66.63%	66.64%	66.29%	66.49%	66.47%	66.5%	66.52%	69.58%	68.28%
No. of shareholders	—	—	—	—	—	—	—	—	17,282	17,251	16,636	14,510

Promoter holding down 2.9 percentage points since Sep 2023.

59 deals · 23 Mar 2022 – 11 Nov 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
11 Nov 2025	ELIMATH ADVISORS PRIVATE LIMITED	Bulk	NSE	Buy	38,40,000	₹73.47	₹28.21 Cr
11 Nov 2025	ELIZABETH MATHEW	Bulk	NSE	Sell	38,40,000	₹73.45	₹28.20 Cr
29 Oct 2025	AJIT RAMKARAN SARDA	Bulk	NSE	Buy	2,65,483	₹81.58	₹2.17 Cr
29 Oct 2025	AJIT RAMKARAN SARDA	Bulk	NSE	Sell	1,42,892	₹82.02	₹1.17 Cr
24 Oct 2025	MATHEW CYRIAC	Bulk	NSE	Sell	15,69,000	₹68.84	₹10.80 Cr
24 Oct 2025	ELIMATH ADVISORS PRIVATE LIMITED	Bulk	NSE	Buy	14,97,124	₹68.79	₹10.30 Cr
17 Jul 2025	ELIZABETH MATHEW	Bulk	NSE	Sell	17,94,000	₹115.31	₹20.69 Cr
17 Jul 2025	MATHEW CYRIAC	Bulk	NSE	Buy	17,94,000	₹115.31	₹20.69 Cr
20 Mar 2025	YUGA STOCKS AND COMMODITIES PRIVATE LIMITED	Bulk	NSE	Sell	4,77,321	₹93.51	₹4.46 Cr
20 Mar 2025	YUGA STOCKS AND COMMODITIES PRIVATE LIMITED	Bulk	NSE	Buy	41,859	₹99.73	₹0.42 Cr

1–10 of 59

1 / 6

Mr. Anwar DaudExecutive Director-Chairperson related to Promoter-MD
Mr. Zulfiquar Murtuza KamalExecutive Director
Mr. Niraj Pukhraj DhadiwalExecutive Director
Mr. Prakash Pralahadrao SapkalExecutive Director
Mrs. Kavita LoyaNon-Executive - Independent Director
Mr. Padmakar Shrinivas JoshiNon-Executive - Independent Director
Mr. Kamlesh Bajirao ShendeNon-Executive - Independent Director
Mr. Ashok BhatiaNon-Executive - Independent Director
Mr. Shyam Mohan PatroChief Financial Officer
Piyush NikhadeCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 1 fund houses

Held by these funds

1.18%

of the company's equity

All mutual funds

1.07%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

1 schemes

		Shares
INDIA PHARMA & HEALTHCARE FUND	Tata Mutual Fund	6.31 L	7.74	0.49%	1.18%	-0

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Pursaunt to Regulation 30 of SEBI (Listing Obligations and Disclsoure Requirements) Regulations, 2015, please find attached the disclosure with respect to Credit Rating, for your reference.17 Feb 2026

Investor Presentation and earnings call

Aug 2026Transcript AI SummaryPPTREC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

2

Dividend dividend19 Sept 2019 · ex-date₹0.5
Final dividend3 Sept 2018 · ex-date₹1

1

Board meeting to consider results6 Aug 2026

2

Bonus 2:122 Dec 2022 · ex-date
Bonus 1:14 Oct 2018 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

12 announcementsExport CSV

28 Sept 2026, 12:31 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

18 Sept 2026, 8:11 amCompany Update

Announcement under Regulation 30 (LODR)-Updates on Acquisition

Acquisition PDF

15 Sept 2026, 7:51 pmCompany Update

Announcement under Regulation 30 (LODR)-Updates on Acquisition

Acquisition PDF

12 Aug 2026, 7:20 pmCompany Update

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Earnings Call Transcript PDF

8 Aug 2026, 10:31 amCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Analyst / Investor Meet PDF

7 Aug 2026, 2:52 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

31 Jul 2026, 12:22 pmBoard Meeting

Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended 30Th June, 2026.

Exchange filing PDF

30 Jul 2026, 7:15 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Date	Category	Subject	Filing
28 Sept 2026, 12:31 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
18 Sept 2026, 8:11 am	Company Update Acquisition	Announcement under Regulation 30 (LODR)-Updates on Acquisition

Loading announcements…

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	48.4%	51.9%	50.1%	53.3%	55.7%	55.8%
EBITDA margin %	12.9%	12.3%	13.1%	11.3%	11.5%	8%
EBIT margin %	7.8%	7.5%	8.7%	6.9%	6.2%	2.7%
PAT margin %	2.4%	4.4%	6.1%	4.7%	3.2%	1.6%
Working capital
Receivable days	86	98	87	100	103	106
Inventory days	125	171	99	173	188	207
Payable days	149	185	107	133	151	161
NWC days	62	85	79	140	140	152
Leverage
Current ratio	1.35	1.45	1.72	1.43	1.39	1.45
Debt to EBITDA	2.04	1.25	1.15	2.57	2.57	4.1
Debt to equity	0.5	0.29	0.3	0.45	0.44	0.42
Interest coverage	2.4	3.5	7.3	4.4	2.6	1.6
Asset turnover	0.95	0.98	1.17	0.82	0.8	0.69
Return ratios
Return on assets %	2.3%	4.3%	7.2%	3.9%	2.6%	1.1%
Return on capital employed %	14.4%	15.5%	19.2%	11.8%	9.9%	6.5%
Return on equity %	4.6%	8.3%	12.2%	7.2%	4.8%	2%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

₹ Cr	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	37	35	22	32	49	38	16	41	50
	-26	-21	-19	-6	-15	-36	-73	-40	-56
	-10	-15	-3	-26	-33	1	60	-9	28
Net cash flow	1	-1	1	0	2	2	3	-8	21
Free cash flow	—	—	—	25	34	1	-58	0	5
CFO / Operating profit %	—	—	—	80.1%	120.1%	72.2%	39.4%	94.1%	165%

Zim Laboratories Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

2

1

2

Announcements

2

1

2

Not in the F&O segment

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Zim Laboratories Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Dividends2

Board meetings1

Bonus issues2

Announcements

Dividends2

Board meetings1

Bonus issues2

Ratio timeline

Not in the F&O segment

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

2

1

2

2

1

2